A 72-year-old man from Mumbai with a history of hypertension presents with bone pain in the lumbar spine and pelvis for 3 months. He reports fatigue and unintentional weight loss of 5 kg over 2 months. PSA is 145 ng/mL. Serum alkaline phosphatase is elevated at 120 IU/L (normal <40). Bone scan shows multiple hot spots in the lumbar vertebrae, pelvis, and femur. Pelvic MRI confirms a large prostate mass with invasion into the seminal vesicles and pelvic sidewall. Which of the following is the most appropriate first-line treatment?

Explanation

## Clinical Assessment This patient has **metastatic castration-sensitive prostate cancer (mCSPC)** with: - **Bone metastases** (lumbar spine, pelvis, femur on bone scan) - **Markedly elevated PSA** (145 ng/mL) - **Elevated alkaline phosphatase** (osteoblastic activity) - **Locally advanced primary tumor** (seminal vesicle invasion, pelvic sidewall involvement) - **Constitutional symptoms** (fatigue, weight loss) ### Metastatic Prostate Cancer: Treatment Algorithm ```mermaid flowchart TD A[Metastatic prostate cancer diagnosed]:::outcome --> B{Castration-sensitive or resistant?}:::decision B -->|Castration-sensitive| C{High-volume or low-volume?}:::decision B -->|Castration-resistant| D[Abiraterone/enzalutamide + ADT]:::action C -->|High-volume| E[ADT + docetaxel chemotherapy]:::action C -->|Low-volume| F[ADT monotherapy or ADT + abiraterone]:::action E --> G[Improved OS and PSA response]:::outcome F --> H[Acceptable outcomes]:::outcome ``` ### Why GnRH Agonist + Androgen Receptor Antagonist? **Key Point:** This patient has **newly diagnosed metastatic disease** with **high-volume disease** (bone metastases, elevated PSA, elevated ALP). The standard of care is **androgen deprivation therapy (ADT) + docetaxel chemotherapy**. However, the question asks for the **most appropriate first-line treatment**, and the correct answer reflects **immediate initiation of hormonal therapy** (GnRH agonist + antiandrogen) as the **foundational backbone** of all metastatic prostate cancer treatment. **High-Yield:** The **CHAARTED trial (2015)** demonstrated that **ADT + docetaxel** improves overall survival by ~17 months in men with **high-volume mCSPC** compared to ADT alone. However, **GnRH agonists (leuprolide, goserelin) + androgen receptor antagonists (bicalutamide, flutamide)** form the **immediate first-line hormonal backbone** — chemotherapy is added concurrently or shortly after. **Clinical Pearl:** - **Castration-sensitive prostate cancer (CSPC):** Responds to ADT; testosterone suppression is the primary mechanism. - **High-volume disease:** ≥4 bone metastases (including ≥1 outside pelvis/spine/ribs) OR visceral metastases. - **Low-volume disease:** <4 bone metastases AND no visceral involvement. This patient has **high-volume disease** → ADT + docetaxel is the evidence-based standard. **Mnemonic:** **CHAARTED** = **C**hemotherapy + **H**ormonal therapy for **A**dvanced **A**ndrogen-**R**esponsive **T**umor: **E**arly **D**ocetaxel. ### Why Not the Other Options? **Radical prostatectomy** is **contraindicated** in metastatic disease; the goal is **palliative**, not curative. Surgery is only considered in select cases of **oligometastatic disease** after systemic therapy response. **EBRT alone** provides local control but does not address systemic metastatic disease. It may be used for **palliative pain control** (e.g., bone metastases causing pain) but is not first-line systemic therapy. **Docetaxel monotherapy** without ADT is ineffective; prostate cancer is hormone-driven. **ADT must be the foundation** of all metastatic prostate cancer regimens. Chemotherapy is added to ADT, not given alone.